DRL signs with Hatchtech

Hyderabad based Dr. Reddy's Laboratories said it has signed a commercialization deal with Australi's Hatchtech for the latter's prescription head lice product XEGLYZE Lotion.

As part of this agreement, Dr. Reddy's Lab will pay Hatchtech $10 million, followed by up to $50 million based on per-commercialization milestones and an undisclosed amount based on post-commercialization milestones linked to achievement of annual net sales targets.

The company said in a statement that Hatchtech in September 2014 had announced positive results from its two pivotal phase three clinical studies, evaluating XEGLYZE Lotion as a potential treatment for head lice infestation.

XEGLYZE Lotion is a topical formulation contains ABAMETAPIR, an inhibitor of metalloproteases, has demonstrated both ovicidal and lousicidal activity and offers potential for a more effective treatment using only a single application.

PanTheryx and Dr.Reddys announce Agreement

PanTheryx Inc, a global nutrition company and Dr. Reddy's Laboratories Ltd, an Indian Pharmaceutical company announced today a multi-country supply and licensing agreement. The agreement grants Dr. Reddy's the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention, DiaResQ, for infectious diarrhoea in Asian countries under "RELIQUA" brand name.

DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognized as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.